Ganetespib is under clinical development by Aldeyra Therapeutics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ganetespib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ganetespib overview

Ganetespib (STA-9090) is under development for the treatment of epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, malignant peripheral nerve sheath tumors, sarcomas, malignant pleural mesothelioma. The drug candidate is administered through intravenous route. It is a synthetic, small-molecule that acts by targeting heat shock protein 90 (Hsp90).

It was also under development for the treatment of coronavirus disease 2019 (COVID-19).

It was under development for the treatment of  ocular melanoma, melanoma, hematological cancers including acute lymphoblastic leukemia, chronic myelogenous leukemia, post-transplant  lymphoproliferative diseases, HER2 positive or triple negative breast cancer, squamous cell carcinoma of the head and neck (SCCHN) including oral cavity, oropharynx, larynx or hypopharynx, metastatic esophagogastric cancers, non-small cell lung cancer, relapsed and refractory small-cell lung cancer, metastatic colorectal cancer, rectal adenocarcinoma, gastrointestinal stromal tumor, hepatocellular carcinoma, metastatic pancreatic cancer, gastrointestinal carcinomas, non-squamous non-small cell lung carcinoma, urothelial carcinomas, relapsed or refractory multiple myeloma and metastatic castration-resistant prostate cancer.

Aldeyra Therapeutics overview

Aldeyra Therapeutics, is a biotechnology company. It offers treatment of immune-mediated diseases. The company offers product pipeline includes Reproxalap, ADX-2191, RASP-Inhibitor Discovery Platform, ADX-629, ADX-246 and ADX-248. Reproxalap is used to treat dry eye disease, allergic conjunctivitis and proliferative vitreoretinopathy. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. It develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. Aldeyra Therapeutics is headquartered in Lexington, Massachusetts, the US.

For a complete picture of Ganetespib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.